Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model
about
Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issuesRectal pre-exposure prophylaxis (PrEP)The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsSPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humansA phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 daysMicrobicides and other topical agents in the prevention of HIV and sexually transmitted infections.Progress in antiretroviral drug delivery using nanotechnologyA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groupsInternet treatment of sexually transmitted infections - a public health hazard?Targeting Trojan Horse leukocytes for HIV prevention.Interactions and encapsulation of vitamins C, B3, and B6 with dendrimers in water.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates.A guide for standardizing colposcopic observations for the evaluation of topical microbicide products in the pigtailed macaque model.Rectal microbicide development.A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.Evaluation of cationic polyamidoamine dendrimers' dermal toxicity in the rat skin modelTesting of viscous anti-HIV microbicides using Lactobacillus.Degradation of naturally occurring and engineered antimicrobial peptides by proteases.Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluationRice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV.Animal models for microbicide studies.VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infectionMicrobicide safety/efficacy studies in animals: macaques and small animal models.Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.Dendrimers--revolutionary drugs for infectious diseases.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Application of nanomedicine for crossing the blood-brain barrier: Theranostic opportunities in multiple sclerosis.Rice endosperm produces an underglycosylated and potent form of the HIV-neutralizing monoclonal antibody 2G12.Dendrimers: Breaking the paradigm of current musculoskeletal autoimmune therapies.Early cellular innate immune responses drive Zika viral persistence and tissue tropism in pigtail macaquesDendrimers as topical microbicides with activity against HIVUnexpected Biological Applications of Dendrimers and Specific Multivalency ActivitiesNanosystem formulations for rectal microbicides: a call for more researchImproved Methodology for Monitoring Poly(amidoamine) Dendrimers Surface Transformations and Product Quality by Ultra Performance Liquid Chromatography
P2860
Q26825175-AF6CD344-0BEC-40D9-9A09-D13E5E15EBD0Q26829713-934CD910-5910-4FF6-BDD7-6FC4F987CF55Q28087336-61F3AB38-D422-41EF-8675-B0E573392AE4Q28740364-81FACA83-7DA1-4508-AF9D-8436E9199861Q28743383-2E02A532-7A9F-430D-9FC8-1D53014DFB6FQ30359545-58145875-00B6-41C8-8336-D4861768D85DQ30395011-8D0DAF3A-18E2-4226-A34A-A6AEEC9BC5B1Q30431343-E04FC1CD-9BE5-474C-A2CA-BF3562350183Q30831776-4C9EBA75-4076-4709-85C4-D0F7832BAD5CQ33305714-CCB50C92-1B90-4302-B54F-7A0305AB3F00Q33518390-B2EECC68-6C80-422E-9656-C04AFB378007Q33557251-5049A778-C4B5-4E54-969C-6959589A0A5BQ33821090-91DAF45B-EB72-4CF8-B48E-EA022140C27DQ33896898-E891DF93-B4A1-4D0D-81E8-BAF301947D1DQ34392634-FCA24F4E-DE74-4593-8950-AB001A0CDEF8Q34575590-69C94B38-A3DC-42F1-9876-BFA8B819180FQ34989166-DB211459-7B18-4403-AE66-09287140ABDCQ35012567-860812B6-4CC9-45A1-A5D8-0ADDA2D667BCQ35045703-D82B2EDE-CF60-4FD0-ACDC-EA2C1B449159Q35171371-27AF41AC-1AA2-484D-A5A0-B9A0D55236ABQ35734254-9C3A9A4F-FA64-4DA4-A1C4-0A0AE8FA2B24Q35968180-22E727BB-B1F2-43B2-8C48-265E10476018Q36566183-6526E518-B358-4B8E-BC0B-3D9471569BACQ36896705-3236E3D7-1B27-48FC-AEE1-EB59866A1520Q37017688-64930A44-6987-4F8D-9788-74607C50E598Q37059892-942A31D6-066B-454A-942A-DFD3C18D9BC9Q37223070-5F8E722D-9E58-4D40-846A-8BC4081252EAQ37274721-F618C523-842F-4017-97BE-1DE583061806Q37823446-D10C106D-B941-4FE3-8D2B-DAF6DEF7D5F5Q38023801-B99195B0-831E-4DAA-93BF-DCDF88645540Q38574172-D0BADA92-C853-4E45-819B-602F024DEF07Q38896543-9354D64E-2764-4DB7-BE3C-4AD8DD2F5219Q41111458-49C410B9-D99D-4F3D-B6F0-7C5BB9209373Q47429306-20078C32-E538-4D09-B932-A9999EA25D33Q56338583-2D2DEB7C-31C3-4C4A-963A-2489ECC7AAC5Q57079961-84271293-F94D-46B9-8DBB-EBCD48054566Q57340548-58296BD3-D323-456C-A7BD-2E0393A0E3BEQ57570865-21481D69-AFA6-47C9-8694-5F3FA6A7232AQ58645669-BBE75F89-F28F-4756-A64F-DD80DD04B08C
P2860
Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Preclinical safety and efficac ...... ns in a nonhuman primate model
@ast
Preclinical safety and efficac ...... ns in a nonhuman primate model
@en
Preclinical safety and efficacy assessments of dendrimer-based
@nl
type
label
Preclinical safety and efficac ...... ns in a nonhuman primate model
@ast
Preclinical safety and efficac ...... ns in a nonhuman primate model
@en
Preclinical safety and efficacy assessments of dendrimer-based
@nl
prefLabel
Preclinical safety and efficac ...... ns in a nonhuman primate model
@ast
Preclinical safety and efficac ...... ns in a nonhuman primate model
@en
Preclinical safety and efficacy assessments of dendrimer-based
@nl
P2093
P2860
P1476
Preclinical safety and efficac ...... ns in a nonhuman primate model
@en
P2093
D L Patton
S L Hillier
T D McCarthy
Y T Cosgrove Sweeney
P2860
P304
P356
10.1128/AAC.50.5.1696-1700.2006
P407
P577
2006-05-01T00:00:00Z